Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + prednisolone is a combination of two synthetic glucocorticoid corticosteroids. Both drugs act as anti-inflammatory and immunosuppressive agents by binding to the glucocorticoid receptor, modulating gene expression, and suppressing pro-inflammatory cytokines. This combination has been studied for its enhanced antileukemic activity in pediatric acute lymphoblastic leukemia (ALL), where low-dose dexamethasone added to prednisolone can potentiate cytotoxic effects on leukemic cells compared to either agent alone[1][9]. Both drugs are also used in various inflammatory, allergic, autoimmune, and oncologic conditions due to their ability to reduce inflammation and immune responses[3][5][7]. The rationale for combining them is based on their differing pharmacokinetics and potencies—dexamethasone is more potent with a longer duration of action than prednisolone—and evidence suggests that the combination may overcome resistance seen with single-agent therapy in some patients[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + prednisolone.